59 results on '"Distler, J. H."'
Search Results
2. POS0893 FACTORS TO CONSIDER FOR MEASURING THE EFFECT OF LUNG FUNCTION ON PATIENT REPORTED OUTCOMES IN SYSTEMIC SCLEROSIS PATIENTS: ANALYSIS OF THE EUSTAR DATABASE.
3. POS0864 ASSESSMENT OF SYSTEMIC SCLEROSIS RELATED MYOCARDIAL FIBROSIS BY 68Ga-FAPI-04 PET/CT
4. POS0874 GLUCOCORTICOIDS PRESCRIBING PRACTICES IN SYSTEMIC SCLEROSIS: AN ANALYSIS OF THE EUSTAR DATABASE.
5. POS0385 “EFFECTIVE LUNG AGE” IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) IN THE SENSCIS TRIAL
6. POS0477 ATTENUATION OF FIBROBLAST ACTIVATION AND FIBROSIS BY ADROPIN IN A HEDGEHOG-DEPENDENT MANNER
7. POS0467 DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
8. AB0130 DEREGULATION OF TFAM EXPRESSION PROMOTES MITOCHONDRIAL DAMAGE AND FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS
9. POS0476 THE NUCLEAR RECEPTOR TR4 ORCHESTRATES CYTOSKELETAL ORGANIZATION IN A Gα12/ROCK-DEPENDENT MANNER TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS
10. POS0383 CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE.
11. POS0873 PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE
12. POS0450 TEMPORAL MIGRATION OF IMMUNE CELLS FROM PSORIATIC SKIN TO JOINTS INITIATING SYNOVIAL INFLAMMATION IN PSORIATIC ARTHRITIS
13. POS0344 O-GlcNAcylation ON NUP153 REGULATES THE EARLY STAGES OF OSTEOCLASTOGENESIS THROUGH MYC NUCLEAR TRANSLOCATION
14. POS0388 DEVELOPING A SCREENING TOOL FOR THE DETECTION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: THE ILD-RISC RISK SCORE
15. POS0883 BIOPHYSICAL PROPERTIES OF MONOCYTES INDICATE DISEASE ACTIVITY, SEVERITY OF FIBROTIC OR MICROVASCULAR MANIFESTATIONS AND THE RISK FOR PROGRESSION IN SYSTEMIC SCLEROSIS
16. OP0245 ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS
17. POS0861 EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT
18. OP0201 DYNAMIC CHANGES IN O-GLCNACYLATION REGULATE OSTEOCLAST DIFFERENTIATION AND BONE LOSS IN ARTHRITIS
19. POS0835 DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE
20. POS0328 ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING
21. AB0091 INHIBITION OF AUTOPHAGY PREVENTS PROGRESSION OF FIBROSIS IN MURINE MODELS OF SYSTEMIC SCLEROSIS
22. AB0410 S100A4 PLASMA LEVELS CORRELATE WITH DISEASE ACTIVITY, SKIN FIBROSIS AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS
23. OP0272 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
24. AB0420 CIRCULATING MONOCYTES HAVE DISTINCT PHYSICAL PROPERTIES THAT CORRELATE WITH DISEASE ACTIVITY AND SEVERITY AND PREDICT PROGRESSION IN SYSTEMIC SCLEROSIS
25. POS0327 INACTIVATION OF ALDEHYDE DEHYDROGENASE 3A2 INHIBITS FIBROBLAST ACTIVATION AND TISSUE FIBROSIS
26. OP0242 EFFECTS OF THE AUTOTAXIN INHIBITOR ZIRITAXESTAT ON SKIN AND LUNG FIBROSIS IN A MURINE GRAFT-VERSUS-HOST DISEASE MODEL OF SYSTEMIC SCLEROSIS
27. POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING
28. Interleukin-1 is essential for systemic inflammatory bone loss
29. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
30. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
31. THU0057 Inhibition of Heat Shock Protein 90 (Hsp90) Prevents Fibrosis by Targeting Canonical TGF-B Signaling
32. THU0114 The Loss of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model
33. SP0090 Fibrotic Disease Models
34. OP0124 Inhibition of Autophagy Rescue the Bone Loss of Experimental Osteoporosis
35. OP0229 MIR-193B Induces uPA in SSC and Contributes to the Proliferative Vasculopathy Via uPAR Independent Pathways
36. THU0055 The Nuclear Receptor Vitamin D Receptor Regulates TGF-ß Signaling and Fibroblast Activation in Systemic Sclerosis
37. OP0228 Protective Effect of LPA1 and 3 Receptor Antagonism in Experimental Skin Fibrosis is Linked to LPA Activity in Dermal Fibroblasts of SSC Patients
38. Heart involvement in patients with systemic sclerosis is mimicked by Fra-2 transgenic mice
39. Inhibition of glycogen synthase kinase 3 induces dermal fibrosis by activation of the canonical Wnt pathway
40. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease
41. The transcription factor JunD mediates transforming growth factor -induced fibroblast activation and fibrosis in systemic sclerosis
42. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
43. Activation of Hedgehog signalling plays a crucial role in the pathogenesis of systemic sclerosis
44. 5-HT release from platelets and activation of 5-HT2B play a crucial role for development of fibrosis in systemic sclerosis
45. Proteasome inhibition aggravates tumour necrosis factor-mediated bone resorption
46. Promoter hypermethylation of the anti-fibrotic gene socs-3 by TGF as novel mechanism in the pathogenesis of SSc
47. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus
48. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies
49. Interleukin-1 is essential for systemic inflammatory bone loss
50. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.